Published in Prog Neurobiol on March 04, 2008
The vitamin nicotinamide: translating nutrition into clinical care. Molecules (2009) 1.36
A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev (2009) 1.31
Perinatal hypoxic-ischemic encephalopathy. J Biomed Biotechnol (2010) 1.23
Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev (2010) 1.21
SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets (2012) 1.14
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol (2012) 1.13
Erythropoietin and oxidative stress. Curr Neurovasc Res (2008) 1.07
Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr Neurovasc Res (2010) 1.06
Clever cancer strategies with FoxO transcription factors. Cell Cycle (2008) 1.05
Oxidative stress: Biomarkers and novel therapeutic pathways. Exp Gerontol (2010) 1.04
Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res (2011) 1.04
Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) (2012) 1.04
The "O" class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol (2009) 1.04
Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr Neurovasc Res (2011) 1.04
Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways. Curr Neurovasc Res (2008) 1.03
Isotretinoin and FoxO1: A scientific hypothesis. Dermatoendocrinol (2011) 1.02
EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes. Curr Neurovasc Res (2011) 1.01
The forkhead transcription factor FOXO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res (2009) 1.01
FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol (2010) 1.00
FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond) (2009) 0.99
Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci U S A (2009) 0.99
New strategies for Alzheimer's disease and cognitive impairment. Oxid Med Cell Longev (2010) 0.98
Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways. Oxid Med Cell Longev (2010) 0.98
Erythropoietin: new directions for the nervous system. Int J Mol Sci (2012) 0.95
Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade. Int J Mol Sci (2012) 0.94
Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease. Neural Regen Res (2015) 0.94
Generation of biologically active multi-sialylated recombinant human EPOFc in plants. PLoS One (2013) 0.93
Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res (2010) 0.93
Translating cell survival and cell longevity into treatment strategies with SIRT1. Rom J Morphol Embryol (2011) 0.93
A fork in the path: Developing therapeutic inroads with FoxO proteins. Oxid Med Cell Longev (2010) 0.92
PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS One (2012) 0.92
Standardized environmental enrichment supports enhanced brain plasticity in healthy rats and prevents cognitive impairment in epileptic rats. PLoS One (2013) 0.92
Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiol (2012) 0.92
Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr Med Chem (2011) 0.91
Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress. Cell Signal (2010) 0.91
Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. ScientificWorldJournal (2009) 0.90
FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Curr Neurovasc Res (2009) 0.90
Non-erythropoietic erythropoietin derivatives protect from light-induced and genetic photoreceptor degeneration. Hum Mol Genet (2011) 0.89
Novel avenues of drug discovery and biomarkers for diabetes mellitus. J Clin Pharmacol (2010) 0.86
Novel directions for diabetes mellitus drug discovery. Expert Opin Drug Discov (2012) 0.86
Systemic and Cerebral Vascular Endothelial Growth Factor Levels Increase in Murine Cerebral Malaria along with Increased Calpain and Caspase Activity and Can be Reduced by Erythropoietin Treatment. Front Immunol (2014) 0.84
mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. World J Diabetes (2015) 0.84
FoxO proteins in the nervous system. Anal Cell Pathol (Amst) (2015) 0.83
Therapeutic promise and principles: metabotropic glutamate receptors. Oxid Med Cell Longev (2010) 0.82
Programming apoptosis and autophagy with novel approaches for diabetes mellitus. Curr Neurovasc Res (2015) 0.81
Otoprotective effects of erythropoietin on Cdh23erl/erl mice. Neuroscience (2013) 0.81
Erythropoietin and diabetes mellitus. World J Diabetes (2015) 0.80
Phagocyte respiratory burst activates macrophage erythropoietin signalling to promote acute inflammation resolution. Nat Commun (2016) 0.78
Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PLoS One (2014) 0.77
Regeneration in the nervous system with erythropoietin. Front Biosci (Landmark Ed) (2016) 0.76
Charting a course for erythropoietin in traumatic brain injury. J Transl Sci (2016) 0.76
Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy. Curr Neurovasc Res (2016) 0.75
Age-associated expression of erythropoietin and its receptor in rat spiral ganglion neurons and its association with neuronal apoptosis and hearing alterations. Mol Med Rep (2016) 0.75
FOXO Signaling Pathways as Therapeutic Targets in Cancer. Int J Biol Sci (2017) 0.75
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 75.82
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell (1997) 24.57
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Signaling to NF-kappaB. Genes Dev (2004) 19.78
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med (2004) 18.86
Mechanisms of angiogenesis. Nature (1997) 18.04
The mechanism of pancreatic secretion. J Physiol (1902) 15.82
Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature (2000) 13.45
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA (2006) 11.78
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet (2003) 11.47
Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science (2003) 11.39
Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes (2002) 10.49
Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (1998) 9.56
Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol (1998) 9.24
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Purification and characterization of hypoxia-inducible factor 1. J Biol Chem (1995) 8.53
Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem (1999) 8.16
Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev (2000) 7.81
Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature (1993) 7.56
Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A (1990) 7.39
Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood (2001) 6.35
Cloning of a factor required for activity of the Ah (dioxin) receptor. Science (1991) 5.84
Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med (2007) 5.63
Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol (2006) 5.56
A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell (2006) 5.36
Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell (2001) 5.19
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol (2005) 4.82
Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell (1999) 4.69
Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med (2007) 4.65
Trends in oxidative aging theories. Free Radic Biol Med (2007) 4.51
The movements and innervation of the small intestine. J Physiol (1901) 4.45
Erythropoietin. Blood (1991) 4.37
Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature (1985) 4.23
A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med (2007) 4.12
Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09
Type 1 diabetes. Lancet (2006) 3.61
Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol (2001) 3.43
Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem (2007) 3.35
The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol (2000) 3.34
Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A (1985) 3.28
New avenues of exploration for erythropoietin. JAMA (2005) 3.23
14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol (2002) 2.97
Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood (2003) 2.93
Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem (2000) 2.89
beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci (2001) 2.81
HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med (2002) 2.69
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004) 2.64
Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A (1994) 2.61
Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes (2006) 2.58
Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol (2001) 2.52
Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation (2003) 2.49
The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol (2004) 2.47
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol (1991) 2.47
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol (2001) 2.45
Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol (2005) 2.44
Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation (2002) 2.37
Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) (2003) 2.35
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A (1990) 2.28
Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes (1999) 2.19
Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol (2007) 2.13
Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology (2004) 2.10
Recombinant human erythropoietin prevents the death of mice during cerebral malaria. J Infect Dis (2006) 2.06
The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci (1997) 2.02
Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res (2006) 2.02
Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia (2006) 2.02
A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science (2004) 1.95
Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol (2005) 1.94
Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation. Am J Physiol Heart Circ Physiol (2007) 1.92
Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci (1996) 1.91
Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J Biol Chem (1996) 1.88
Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J (1995) 1.87
Caspase activation: revisiting the induced proximity model. Cell (2004) 1.85
Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med (2001) 1.83
Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging (2000) 1.83
Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res (2002) 1.79
Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci (2007) 1.77
Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol (2002) 1.75
Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology (2004) 1.70
Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest (2006) 1.69
Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab (2006) 1.68
Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol (2000) 1.68
Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J (2007) 1.67
Wnts: up-and-coming at the synapse. Trends Neurosci (2007) 1.67
High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol (2005) 1.66
Wnt10b inhibits obesity in ob/ob and agouti mice. Diabetes (2007) 1.65
Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A (2003) 1.64
The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol (2007) 1.63
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J (2007) 1.62
Healthcare utilization and costs in managed care patients with Alzheimer's disease during the last few years of life. J Am Geriatr Soc (2001) 1.61
Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem (2007) 1.60
Akt/protein kinase B prevents injury-induced motoneuron death and accelerates axonal regeneration. J Neurosci (2000) 1.59
Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem (2000) 1.58
Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci (2007) 1.58
Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem (1988) 1.58
Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci (2005) 1.55
Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J (2007) 1.55
Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol (2003) 1.54
Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein. J Biol Chem (2001) 1.51
New avenues of exploration for erythropoietin. JAMA (2005) 3.23
Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol (2005) 2.44
mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med (2012) 1.59
OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med (2008) 1.52
Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res (2007) 1.48
The Wnt signaling pathway: aging gracefully as a protectionist? Pharmacol Ther (2008) 1.38
The vitamin nicotinamide: translating nutrition into clinical care. Molecules (2009) 1.36
Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol (2003) 1.34
A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev (2009) 1.31
Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci (2003) 1.31
Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci (2004) 1.30
Cell Life versus cell longevity: the mysteries surrounding the NAD+ precursor nicotinamide. Curr Med Chem (2006) 1.28
Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res (2005) 1.26
Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem (2007) 1.25
Life span extension and neuronal cell protection by Drosophila nicotinamidase. J Biol Chem (2008) 1.23
Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res (2006) 1.22
Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev (2010) 1.21
Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res (2007) 1.21
Vital elements of the Wnt-Frizzled signaling pathway in the nervous system. Curr Neurovasc Res (2005) 1.21
Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev (2005) 1.19
The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mitochondrial associated "anti-apoptotic" pathways. Curr Neurovasc Res (2005) 1.19
Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal (2007) 1.16
Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets (2012) 1.14
SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets (2012) 1.14
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol (2012) 1.13
The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med (2007) 1.13
Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals (2005) 1.13
"Sly as a FOXO": new paths with Forkhead signaling in the brain. Curr Neurovasc Res (2007) 1.12
Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J Neurosci Res (2003) 1.10
Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress. Curr Neurovasc Res (2006) 1.10
mGluRI targets microglial activation and selectively prevents neuronal cell engulfment through Akt and caspase dependent pathways. Curr Neurovasc Res (2005) 1.10
Erythropoietin and oxidative stress. Curr Neurovasc Res (2008) 1.07
Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr Neurovasc Res (2010) 1.06
Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restor Neurol Neurosci (2004) 1.05
Clever cancer strategies with FoxO transcription factors. Cell Cycle (2008) 1.05
Oxidative stress: Biomarkers and novel therapeutic pathways. Exp Gerontol (2010) 1.04
The "O" class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol (2009) 1.04
Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res (2011) 1.04
Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) (2012) 1.04
Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr Neurovasc Res (2011) 1.04
Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomed Pharmacother (2008) 1.02
Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. Curr Neurovasc Res (2005) 1.01
EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes. Curr Neurovasc Res (2011) 1.01
The forkhead transcription factor FOXO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res (2009) 1.01
Study of a "biological focal region" of high-intensity focused ultrasound. Ultrasound Med Biol (2003) 1.00
FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol (2010) 1.00
Cardiovascular disease and mTOR signaling. Trends Cardiovasc Med (2011) 1.00
Raves and risks for erythropoietin. Cytokine Growth Factor Rev (2008) 0.99
FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond) (2009) 0.99
New strategies for Alzheimer's disease and cognitive impairment. Oxid Med Cell Longev (2010) 0.98
Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways. Oxid Med Cell Longev (2010) 0.98
Perfluorohexane-encapsulated mesoporous silica nanocapsules as enhancement agents for highly efficient high intensity focused ultrasound (HIFU). Adv Mater (2012) 0.96
Erythropoietin: new directions for the nervous system. Int J Mol Sci (2012) 0.95
WISP1 (CCN4) autoregulates its expression and nuclear trafficking of β-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr Neurovasc Res (2012) 0.95
Attempted cell cycle induction in post-mitotic neurons occurs in early and late apoptotic programs through Rb, E2F1, and caspase 3. Curr Neurovasc Res (2006) 0.95
Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL. Curr Neurovasc Res (2012) 0.95
Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade. Int J Mol Sci (2012) 0.94
Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res (2010) 0.93
Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better? Curr Neurovasc Res (2005) 0.93
Translating cell survival and cell longevity into treatment strategies with SIRT1. Rom J Morphol Embryol (2011) 0.93
A fork in the path: Developing therapeutic inroads with FoxO proteins. Oxid Med Cell Longev (2010) 0.92
PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS One (2012) 0.92
Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiol (2012) 0.92
Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress. Cell Signal (2010) 0.91
Navigating novel mechanisms of cellular plasticity with the NAD+ precursor and nutrient nicotinamide. Front Biosci (2004) 0.91
WISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1. Curr Neurovasc Res (2013) 0.91
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. Future Neurol (2012) 0.90
Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. ScientificWorldJournal (2009) 0.90
Rogue proliferation versus restorative protection: where do we draw the line for Wnt and forkhead signaling? Expert Opin Ther Targets (2008) 0.90